Skip to content

Pipeline

During the fourth quarter 2019, Aqilion launched the new innovative discovery program Alnitak and in September 2020, the discovery program Polaris was launched. In December 2021, Aqilion’s pipeline was strengthened through the acquisition of a phase 1 ready anti-inflammatory program, now under the name Regulus.

In May 2022, the drug development program Girtab for the treatment of inflammatory bowel diseases (IBD) was added to the company’s pipeline.

Program
Target
Drug Candidate
Target Discovery
Development of Drug Candidate
IND enabling preclinical development
Phase 1
Phase 2
Regulus
JAK1
AQ280
Girtab
AhR
AQ312
Alnitak
TAK1
Not disclosed
Alnitak
TAK1 CNS penetrant
Not disclosed
Polaris
Not disclosed
Not disclosed